Trailing Twelve Months Revenue Growth: Fennec (FENC)

Public company logo of fennecpharma.com (FENC)

The diversification of pediatric hearing protection programs during chemotherapy impacts the TTM year-over-year sales growth rate for Fennec Pharmaceuticals (FENC), where the 70.90 metric serves as the target level. Financial stability is based on the creation of an irreplaceable treatment ecosystem. The monopoly status of Pedmark and FDA orphan drug privileges establish insurmountable barriers to entry for competitors, ensuring long-term protection of the market niche.

Fennec Pharmaceuticals (FENC): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/17/2026

Fennec Pharmaceuticals - analytical breakdowns and key metrics (FENC)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:Fennec Pharmaceuticals Inc
Brand item of Fennec

Fennec Pharmaceuticals' status as a monopolist in pediatric hearing protection during chemotherapy creates a foundation for the stable extraction of high rents. This metric, which has reached 70.90, measures the rate of revenue change over the last 12 months relative to the same period last year, allowing for an assessment of the drug's commercialization speed and the business's long-term scaling potential through the TTM revenue growth trajectory compared to the previous year.

Who Fennec Pharmaceuticals competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) HRTX (Heron)|NVCT (Nuvectis Pharma) - Revenue Dynamics YoY (Last Twelve Months)|Coherus Biosciences - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) BYSI (BeyondSpring Pharma)|BCAB: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth lixte.com (LIXT)|Sales Growth YoY (Last Twelve Months) citiuspharma.com|CLRB: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) BLRX|Sales Growth YoY (TTM) Can-Fite (CANF)|Sales Growth YoY (Last Twelve Months) Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Trailing Twelve Months Sales Growth|SLXN: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)